The CDMO plans to allocate most of offering proceeds toward its PolyPeptide Group acquisition, with the remaining funds slated for Bio Campus II investment.
The new 225,000-square-foot facility in Whitestown is expected to expand its radiopharmaceutical manufacturing capacity and create up to 100 jobs by 2029.
The 120,000-liter biologics manufacturing facility in Songdo achieved the rating under South Korea’s Green Standard for Energy and Environmental Design.
